Fusion biopsy market projected to reach USD 2.1 billion by 2034, driven by advanced healthcare infrastructure.
From GlobeNewswire: 2025-01-22 07:03:00
The Fusion biopsy market size was valued at USD 829.1 million in 2024, with a projected 9.9% CAGR from 2025 to 2034. Combining MRI and ultrasound imaging, fusion biopsy enhances diagnostic precision for prostate cancer detection. Devices segment led the market with USD 703.1 million revenue in 2024, crucial for accurate diagnoses.
Fusion biopsy is crucial for detecting prostate cancer accurately, especially in older men. The market is divided into devices and accessories segments, with MRI-ultrasound fusion systems leading in revenue. The method’s precision ensures accurate diagnoses, reducing false negatives, and improving prostate cancer management, especially for active surveillance patients.
The North America fusion biopsy market is a key driver of global market revenue growth, supported by advanced healthcare infrastructure and high prostate cancer incidence rates. Hospitals are the dominant end users of fusion biopsy technology, equipped with the necessary imaging technologies for accurate biopsies.
Major players in the fusion biopsy market include Canon Medical Systems, GE Healthcare, Siemens Healthineers, and more. Fusion biopsy is primarily used for prostate cancer diagnosis, with applications in kidney cancer and other areas. Hospitals are the preferred setting for fusion biopsies due to their advanced infrastructure and trained medical staff.
Read more at GlobeNewswire: Fusion Biopsy Market to hit USD 2.1 billion by 2034, says